LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Inclusion Criteria:

A clinical diagnosis of psoriasis vulgaris of at least 6 months duration involving the trunk and/or limbs
Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2-30% of the Body Surface Area (BSA)
An Investigator's Global Assessment of disease severity (IGA) of at least mild at Day 0 (Visit 1)
A modified PASI (m-PASI) score of at least 2 at Day 0 (Visit 1)
A target lesion of a minimum of 5 cm at its longest axis and preferably not located on the extensor surface on an elbow or knee, scoring at least 1 for each of redness, thickness and scaliness, and at least 4 in total by the Investigator's Assessment of Severity of the Target Lesion

Exclusion Criteria:

Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:

etanercept - within 4 weeks prior to randomisation
adalimumab, infliximab - within 8 weeks prior to randomisation
ustekinumab - within 16 weeks prior to randomisation
other products - within 4 weeks/5 half-lives prior to randomisation (whichever is longer)
Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants) within 4 weeks prior to randomisation.
Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.
PUVA therapy within 4 weeks prior to randomisation.
UVB therapy within 2 weeks prior to randomisation.
Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within 2 weeks prior to randomisation.
Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D analogues or prescription shampoos within 2 weeks prior to randomisation.
Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors) during the trial.
Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.
Previously randomised in this trial or any previously conducted trial of LEO 90100.